Author Archive

Price controls and compulsory licensing give buyers more power … for a price.

Countries use various methods to control drug expenditures. Beyond simple negotiation, countries can also implement price controls or use WTO-authorized compulsory licensing, which enables a country to produce generic versions of branded drugs if they face a health crisis without violating international patent agreements. The United States threatened to use compulsory licensing to acquire cheap […]


Carnival of Biotechnology

Investing and Clinical Trials PharmaGossip has an illuminating excerpt from The End of Medicine describing a method to invest in drug companies as they progress through clinical trials. Ted Love, CEO of Nuvelo Inc., explains how biotechnology companies are frequently able to recover from seemingly disastrous clinical trial failures. Patents When manufacturers seeking to sell […]


Why are biogenerics so hard to regulate?

There’s been a lot of press floating around lately about the push to develop a framework for biogeneric (or biosimilar, or follow-on, etc.) approvals. Why are biogenerics so hard to regulate? Why can’t they just follow the same path as traditional generic drugs? The answer lies in their size and complexity. I’ll use the following […]


Drug Patent Expirations in March 2007

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in March 2007 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration BUDESONIDE Astrazeneca budesonide 4,907,583 MAR 13,2007 FEMPATCH Parke Davis estradiol 4,906,463 MAR 06,2007 GLYNASE Pharmacia And Upjohn glyburide 4,735,805 MAR 11,2007 LOTREL Novartis amlodipine besylate; benazepril hydrochloride 4,879,303 MAR 25,2007 VIDEX […]


Open Biotechnology Journal

I’ve been invited to join the editorial board of the nascent Open Biotechnology Journal. The Open Biotechnology Journal is a peer-reviewed open access journal and aims to publish original research papers in all core areas of biotechnology including basic and applied research, e.g, molecular engineering of nucleic acids and proteins; molecular therapy; imaging technology and […]


Carnival of Biotechnology

Scientific Advances The MaRS Blog has a captivating story of Canada’s recent major diabetes discovery. The first discovery, in 1920, elucidated insulin’s central role in diabetes. The most recent discovery, also from the University of Toronto, has found a strong link between diabetes, pain nerves, and inflammation. Researchers were able to prevent and even reverse […]


Drug Patent Expirations in February 2007

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in February 2007 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration PRECOSE Bayer Pharms acarbose 4,904,769 FEB 27,2007 PREVACID Tap Pharm lansoprazole 6,123,962 FEB 13,2007 PREVACID Tap Pharm lansoprazole 6,749,864 FEB 13,2007 QUADRAMET Cytogen samarium sm 153 lexidronam pentasodium 4,898,724 FEB 06,2007 […]


Carnival of Biotechnology

This edition of the Carnival of Biotechnology features a number of posts on distressing industry trends, some enlightening patent discussion, and interesting commentary on issues in commercialization Industry Trends Forbes presents Genentech’s Next Act. his dialogue with Genentech’s chief officers acknowledges the longshot Genentech was in its early days and plots the future paths Genentech […]


Lessons and analogies from other industries

Guest content from John Avellanet, managing director of Cerulean Associates: As professionals affiliated with the biotechnology industry, we often forget that many of the struggles faced today have been solved before by other fields and industries. As Ambrose Bierce wrote, “There is nothing new under the sun, but there are lots of old things we […]


Can Science Be a Business?

Harvard’s Gary Pisano has recently published a book titled “Science Business: The Promise, the Reality, and the Future of Biotech“ in which he assesses the performance of the biotechnology sector and, in finding it lacking, proceeds to recommend a series of suggestions to improve the fundamental architecture of the industry. While I enjoyed the book […]